Stephen A. Harrison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen A. Harrison has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
A.H. Paredes
3 shared publicationsAijaz Ahmed
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA
3 shared publicationsK.M. Cebe
3 shared publicationsC. Lisanti
2 shared publicationsDawn M. Torres
Walter Reed National Military Medical Center
2 shared publicationsJ.K. Aden
2 shared publications
Latest Publications
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S66-S67
FibroScan-based score to identify patients with non-alcoholic steatohepatitis: development in a multi-centric British cohort and validation in a large American cohort
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S66-S67
FibroScan-based score to identify patients with non-alcoholic steatohepatitis: development in a multi-centric British cohort and validation in a large American cohort
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S109-S110
Prospective prevalence study of adult NAFLD/NASH utilizing multi-modality imaging compared with liver bopsy
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S109-S110
Prospective prevalence study of adult NAFLD/NASH utilizing multi-modality imaging compared with liver bopsy
- 5 August 2016
- Published by Wolters Kluwer Health in Hepatology
- Vol. 64 (6) , 2234-2243
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is now the most common form of liver disease in developed countries, with an estimated prevalence of 20%‐30% and increasing to as high as 90% in diabetics. As the rates of NAFLD continue to rise in parallel with those of the obesity pandemic, it is increasingly important to differentiate those patients with the highest risk of progression to fibrosis and cirrhosis. In fact, those patients with nonalcoholic steatohepatitis (NASH) and fibrosis are at the greatest risk of progression to advanced disease, cirrhosis, and hepatocellular cancer and are more likely to develop liver‐related mortality. Thus, it is critically important to distinguish between NASH and non‐NASH NAFLD. Whereas liver biopsy remains the gold standard for staging of disease, complications of this procedure and other well‐recognized limitations make it impractical for widespread use given the overall NAFLD disease burden. Noninvasive imaging modalities are increasingly being utilized to evaluate and stage NAFLD in patients with such a wide spectrum of disease. In this article, the role of these new and promising noninvasive imaging modalities to assess disease severity in NAFLD are reviewed. (Hepatology2016;64:2234‐2243)
- 5 August 2016
- Published by Wolters Kluwer Health in Hepatology
- Vol. 64 (6) , 2234-2243
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is now the most common form of liver disease in developed countries, with an estimated prevalence of 20%‐30% and increasing to as high as 90% in diabetics. As the rates of NAFLD continue to rise in parallel with those of the obesity pandemic, it is increasingly important to differentiate those patients with the highest risk of progression to fibrosis and cirrhosis. In fact, those patients with nonalcoholic steatohepatitis (NASH) and fibrosis are at the greatest risk of progression to advanced disease, cirrhosis, and hepatocellular cancer and are more likely to develop liver‐related mortality. Thus, it is critically important to distinguish between NASH and non‐NASH NAFLD. Whereas liver biopsy remains the gold standard for staging of disease, complications of this procedure and other well‐recognized limitations make it impractical for widespread use given the overall NAFLD disease burden. Noninvasive imaging modalities are increasingly being utilized to evaluate and stage NAFLD in patients with such a wide spectrum of disease. In this article, the role of these new and promising noninvasive imaging modalities to assess disease severity in NAFLD are reviewed. (Hepatology2016;64:2234‐2243)
- Open Access
- 7 July 2016
- Published by Wolters Kluwer Health in Hepatology
- Vol. 64 (3) , 954
Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges
- 7 July 2016
- Published by Wolters Kluwer Health in Hepatology
- Vol. 64 (3) , 954
Open AccessNonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges
- 1 May 2016
- Published by Elsevier in Clinics in Liver Disease
- Vol. 20 (2) , 339-350
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
- 1 May 2016
- Published by Elsevier in Clinics in Liver Disease
- Vol. 20 (2) , 339-350
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
- 6 April 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (5) , 1365-1374
Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
NAFLD is the leading cause of chronic liver disease in the Western world with an estimated prevalence of 20–30 %. Lifestyle interventions targeted at weight loss through dietary interventions and exercise are the most effective treatment, but only a minority of patients are able to achieve and sustain the necessary intervention targets. Weight loss of 3–5 % has been associated with a reduction of hepatic steatosis while weight loss of ≥5–7 % has correlated with resolution of NASH in some studies. Greater reductions in weight loss (≥10 %) may improve hepatic fibrosis. In the absence of weight loss, no specific diet has demonstrated superiority. Physical activity can improve hepatic steatosis and metabolic indices even without weight loss. Diet coupled with exercise can produce significant weight loss and may improve histologic components of the NAFLD activity score. While formal guidelines for diet and exercise in NAFLD are lacking, adherence to diet and exercise recommendations similar to those from the American Diabetes Association for diabetic care seems reasonable. Dietary supplementation with vitamin E in non-diabetics with biopsy-proven NASH has been shown to improve NAFLD activity score. The role for other macronutrients, micronutrients, antioxidants, and probiotics in the treatment of NAFLD remains limited.
- 6 April 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (5) , 1365-1374
Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
NAFLD is the leading cause of chronic liver disease in the Western world with an estimated prevalence of 20–30 %. Lifestyle interventions targeted at weight loss through dietary interventions and exercise are the most effective treatment, but only a minority of patients are able to achieve and sustain the necessary intervention targets. Weight loss of 3–5 % has been associated with a reduction of hepatic steatosis while weight loss of ≥5–7 % has correlated with resolution of NASH in some studies. Greater reductions in weight loss (≥10 %) may improve hepatic fibrosis. In the absence of weight loss, no specific diet has demonstrated superiority. Physical activity can improve hepatic steatosis and metabolic indices even without weight loss. Diet coupled with exercise can produce significant weight loss and may improve histologic components of the NAFLD activity score. While formal guidelines for diet and exercise in NAFLD are lacking, adherence to diet and exercise recommendations similar to those from the American Diabetes Association for diabetic care seems reasonable. Dietary supplementation with vitamin E in non-diabetics with biopsy-proven NASH has been shown to improve NAFLD activity score. The role for other macronutrients, micronutrients, antioxidants, and probiotics in the treatment of NAFLD remains limited.
- 1 January 2016
- Published by Springer Nature
- p. 183-194
Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers, and Natural History
- 1 January 2016
- Published by Springer Nature
- p. 183-194
Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers, and Natural History
- 20 November 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 63 (1) , 20-22
High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?
- 20 November 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 63 (1) , 20-22
High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?
- Top Cited Papers
- 1 November 2015
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 13 (12) , 2062-2070
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
- 1 November 2015
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 13 (12) , 2062-2070
Top Cited PapersNonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes